Biotechnology · Nasdaq

AMGNAmgen Inc

Last close
$465.67 -0.3%
52-week range
$312.38 to $483.99
Market cap
$252B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$36.8B
+10% vs FY24
Net income
$7.71B
+89% vs FY24
Free cash flow
$8.10B
-22% vs FY24
Net cash
-$45.5B
Cash $9.13B, debt $54.6B

Stock price

+225% since Dec 2016

Valuation vs its own 10 years

Above its 10-year median on all 4 multiples

Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.

P/E, trailing
27.0x
14.3x67.7x
78th percentile, above its median of 21.7x
Price / sales
6.5x
4.2x6.5x
Highest point in its range, above its median of 5.2x
EV / EBITDA
17.1x
8.9x19.7x
90th percentile, above its median of 13.3x
Price / free cash flow
26.3x
11.2x30.8x
95th percentile, above its median of 14.4x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
27.0x
Earnings yield
3.7%
Price / sales
6.5x
Price / book
17.6x
Price / operating cash flow
20.9x
EV / EBITDA
17.1x
EV / sales
7.5x
Free cash flow yield
3.8%

Profitability

Gross margin
70.9%
Operating margin
32.4%
Net margin
24.1%
Return on equity
65.4%
Return on capital
15.7%

Growth per year

Revenue, 3 years
+11.8%
Revenue, 5 years
+7.6%
Revenue, 9 years
+5.3%
EPS, 3 years
+5.5%

Balance sheet

Cash and investments
$13.2B
Total debt
$54.0B
Net cash
-$40.8B
Debt / equity
3.76x
Current ratio
1.48x

Shares and dividend

Shares outstanding
541M
Share count, 5 years
-8.1%
Beta, 1 year
0.49
Dividend yield
2.2%
Dividend per share, TTM
$10.08
Payout ratio
57.1%

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $10.4B
RevenueNet income
Gross profitLatest quarter $7.58B
EBITDALatest quarter $4.83B
Margins73 / 36 / 37%
GrossOperatingNet
Earnings per shareLatest quarter $7.08
Cash flowLatest quarter $4.24B
OperatingCapexFree
Cash vs debtLatest quarter $13.2B
Cash and investmentsTotal debt
P/E historyNow 27.0x
P/E, median 21.7x dashed
P/S historyNow 6.5x
P/S, median 5.2x dashed

Where the revenue comes from

Product went from 94% to 96% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

ProductTEPEZZA
FY22
94%
$26.3B
FY23
95%
$28.2B
FY24
96%
$33.4B
FY25
96%
$36.8B
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
Product$35.1B95.6%+10%
TEPEZZA$1.90B5.2%n/a

Biotechnology peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
ONC BeOne Medicines Ltd. $619B +33% 17.8%689x93.6x Not enough history
ABBV AbbVie Inc. $521B +11% 32.2%50.8x7.9x 72nd percentile
AMGN Amgen Inc $252B +8% 32.4%27.0x6.5x 78th percentile
GILD Gilead Sciences, Inc. $208B +7% -7.6%No earnings6.7x No earnings
VRTX Vertex Pharmaceuticals Inc / Ma $137B +10% 33.2%34.7x10.5x 71st percentile
MRNA Moderna, Inc. $90.4B +13% -116%No earnings35.8x No earnings

The company

Sector
Health Care
Industry
Biotechnology
Employees
17,900 (as of 2014)
Founded
1980
Headquarters
Thousand Oaks, CA
Fiscal year ends
December
Website
amgen.com

What it does

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about AMGN.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 2,852 active funds. Crowd level: quiet.

Open the Smart money tab